Literature DB >> 25276408

Therapeutic approaches in the management of locally advanced rectal cancer.

Simon D Fung-Kee-Fung1.   

Abstract

Combined-modality therapy, using radiotherapy and chemotherapy with surgery, has been the traditional therapeutic algorithm for locally advanced rectal cancer. Standard of care in the United States has evolved to include neoadjuvant concurrent chemotherapy and radiotherapy followed by surgical excision and adjuvant chemotherapy. This approach has led to a significant improvement in local recurrences (LR), to the point where distant sites are the more common site of failure. Further improvements in local control have failed to improve overall survival. This article reviews historical trials that shifted the treatment paradigm to the current standard of care, as well as recent research trials, which have sought to incorporate new treatment methodologies, and treatment agents to improve outcomes. Finally this article describes ongoing studies and their potential impact on the future of therapeutic management of locally-advanced rectal cancer.

Entities:  

Keywords:  Rectal cancer; combined modality therapy; neoadjuvant therapy; radiation therapy

Year:  2014        PMID: 25276408      PMCID: PMC4173042          DOI: 10.3978/j.issn.2078-6891.2014.067

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  49 in total

1.  Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Authors:  Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

2.  Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy.

Authors:  L L Gunderson; H Sosin
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  A new approach to rectal cancer.

Authors:  R J Heald
Journal:  Br J Hosp Med       Date:  1979-09

4.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

7.  The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.

Authors:  John M Robertson; David Lockman; Di Yan; Michelle Wallace
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-27       Impact factor: 7.038

8.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.

Authors:  Keisuke Uehara; Kazuhiro Hiramatsu; Atsuyuki Maeda; Eiji Sakamoto; Masaya Inoue; Satoshi Kobayashi; Yuichiro Tojima; Yuichiro Yoshioka; Goro Nakayama; Hiroshi Yatsuya; Naoki Ohmiya; Hidemi Goto; Masato Nagino
Journal:  Jpn J Clin Oncol       Date:  2013-08-09       Impact factor: 3.019

10.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

View more
  2 in total

1.  Rectal cancer: a truly multidisciplinary challenge.

Authors:  Timothy D Wagner
Journal:  J Gastrointest Oncol       Date:  2014-10

2.  TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy.

Authors:  Hui Zhang; Mengyun Wang; Tingyan Shi; Lijun Shen; Liping Liang; Yun Deng; Guichao Li; Ji Zhu; Yongxin Wu; Ming Fan; Weijuan Deng; Qingyi Wei; Zhen Zhang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.